117 related articles for article (PubMed ID: 20199813)
1. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.
Bobo WV; Jayathilake K; Lee MA; Meltzer HY
Psychiatry Res; 2010 Apr; 176(2-3):114-9. PubMed ID: 20199813
[TBL] [Abstract][Full Text] [Related]
2. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics.
Bobo WV; Jayathilake K; Lee MA; Meltzer HY
Hum Psychopharmacol; 2009 Jul; 24(5):415-22. PubMed ID: 19551763
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
4. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia.
Kivircik BB; Alptekin K; Calişkan S; Cömlekçi A; Orük G; Tümüklü M; Kürklü K; Arkar H; Türk A; Calişkan M; Yeşil S
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):795-9. PubMed ID: 12921912
[TBL] [Abstract][Full Text] [Related]
5. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jan; 59(1):7-16. PubMed ID: 12413636
[TBL] [Abstract][Full Text] [Related]
6. Clozapine and body mass change.
Frankenburg FR; Zanarini MC; Kando J; Centorrino F
Biol Psychiatry; 1998 Apr; 43(7):520-4. PubMed ID: 9547931
[TBL] [Abstract][Full Text] [Related]
7. Melperone in the treatment of neuroleptic-resistant schizophrenia.
Meltzer HY; Sumiyoshi T; Jayathilake K
Psychiatry Res; 2001 Dec; 105(3):201-9. PubMed ID: 11814539
[TBL] [Abstract][Full Text] [Related]
8. Effects of clozapine on cognitive function in schizophrenia.
Lee MA; Thompson PA; Meltzer HY
J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
[TBL] [Abstract][Full Text] [Related]
9. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
[TBL] [Abstract][Full Text] [Related]
10. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
11. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics.
Mäkikyrö T; Leinonen E; Koponen H; Järvelin MR; Hakko H; Saarnisaari O; Isohanni M
J Psychiatr Res; 1998; 32(2):105-10. PubMed ID: 9694006
[TBL] [Abstract][Full Text] [Related]
12. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics.
Zhang XY; Tan YL; Zhou DF; Cao LY; Wu GY; Xu Q; Shen Y; Haile CN; Kosten TA; Kosten TR
J Psychiatr Res; 2007 Dec; 41(12):997-1004. PubMed ID: 17095017
[TBL] [Abstract][Full Text] [Related]
13. Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study.
Dursun SM; Szemis A; Andrews H; Whitaker P; Reveley MA
J Psychiatry Neurosci; 2000 Sep; 25(4):347-52. PubMed ID: 11022399
[TBL] [Abstract][Full Text] [Related]
14. Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs.
Sitburana O; Rountree S; Ondo WG
J Neurol Sci; 2008 Sep; 272(1-2):77-82. PubMed ID: 18556024
[TBL] [Abstract][Full Text] [Related]
15. [Atypical neuroleptics and selective attention].
Stip E; Lussier I; Lalonde P; Luyet A; Fabian J
Encephale; 1999; 25(3):260-4. PubMed ID: 10434152
[TBL] [Abstract][Full Text] [Related]
16. [A new therapeutic approach tp drug-resistant schizophrenia: clozapine. Long-term prospective study in 16 patients].
Jalenques I; Coudert AJ
Acta Psychiatr Belg; 1992; 92(6):323-38. PubMed ID: 1364281
[TBL] [Abstract][Full Text] [Related]
17. Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia.
Röhricht F; Gadhia S; Alam R; Willis M
ScientificWorldJournal; 2012; 2012():512047. PubMed ID: 22566771
[TBL] [Abstract][Full Text] [Related]
18. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs.
Meltzer HY; Koenig JI; Nash JF; Gudelsky GA
Acta Psychiatr Scand Suppl; 1989; 352():24-9. PubMed ID: 2573238
[TBL] [Abstract][Full Text] [Related]
19. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jul; 62(1-2):65-72. PubMed ID: 12765745
[TBL] [Abstract][Full Text] [Related]
20. The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: clozapine versus classical antipsychotic agents.
Spivak B; Musin E; Mester R; Gonen N; Talmon Y; Guy N; Roitman S; Kupchik M; Kotler M; Weizman A
Int Clin Psychopharmacol; 1999 Jul; 14(4):229-32. PubMed ID: 10468315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
